News

Rapid antibody screening can help identify stronger antibody candidates earlier in immunoassay development. Fleet supports antibody screening across lateral flow, ELISA, Gyrolab™ and other assay formats, with small-volume screening approaches and in-house bioconjugation capability to support better assay decisions.

Antibody selection is one of the most influential decisions made during early Lateral Flow Assay (LFA) development. Whether antibodies are sourced commercially or developed as part of a broader LFA development service, the choices made at this stage directly affect assay sensitivity, specificity, reproducibility and long-term manufacturability. Applying a structured, risk based approach to antibody evaluation can significantly reduce technical and commercial challenges later